Elotuzumab

From Self-sufficiency

Revision as of 18:44, 13 March 2010 by Anypodetos (Talk) (Added mab_type, updated source)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Elotuzumab
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	SLAMF7 (CD319)
Identifiers
CAS Number	915296-00-3
ATC code	none
Chemical data
Formula	C₆₄₇₆H₉₉₈₂N₁₇₁₄O₂₀₁₆S₄₂
Molar mass	145.5 kDa[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Elotuzumab (also known as HuLuc63) is a humanized monoclonal antibody which is presently under phase I clinical investigation in relapsed multiple myeloma.^[1]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

v t e Humanized monoclonal antibodies ("-zu-")
"-tuzu-" (tumor)	Afutuzumab, Alemtuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Dacetuzumab, Elotuzumab^†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab^§, Milatuzumab, Nimotuzumab, Oportuzumab monatox, Pertuzumab, Sibrotuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab
"-lizu-" (immune system)	immunosuppressive: Aselizumab, Apolizumab, Benralizumab^†, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, PRO 140^†, Reslizumab, Rontalizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412^§ non-immunosuppressive: Ibalizumab^†
"-bazu-" (bacterial)	Tefibazumab^†
"-cizu-" (cardiovascular)	Alacizumab pegol, Bevacizumab/Ranibizumab, Etaracizumab, Tadocizumab
"-nezu-"/"-neuzu-" (nervous system)	Bapineuzumab^†, Solanezumab, Tanezumab
"-toxazu-" (toxin as target)	Urtoxazumab
"-vizu-" (viral)	Felvizumab, Motavizumab, Palivizumab
"-kizu-" (interleukin as target)	Lebrikizumab
"-anibizu-" (angiogenesis inhibitor)	Ranibizumab
^†Undergoing clinical trials. ^§Never marketed.